By Robb M. Stewart
Lantheus's shares were under pressure Wednesday after the radiopharmaceutical-focused company trimmed its earnings target for the year.
In premarket trading, the shares were 13% lower after ending the previous session at $104.84, up 17% so far in 2025 and 38% higher over the last 12 months.
The company lowered its guidance for the adjusted earnings in 2025 to between $6.60 and $6.70 a share on revenue of $1.55 billion to about $1.59 billion. In late February, it was aiming for earnings of $7 to $7.20 on revenue of between about $1.55 billion and $1.61 billion.
Lantheus recorded net income of $72.9 million, or $1.02 a share, for the first quarter, down sharply from $131.1 million, or $1.87 a share, a year earlier.
On an adjusted basis, per-share earnings came in at $1.53, below the $1.66 mean estimate of analysts polled by FactSet.
The company's worldwide revenue was little changed for the quarter, edging up less than 1% to $372.8 million but falling short of the $379.7 million that analysts expected.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
May 07, 2025 08:54 ET (12:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。